Compare AstraZeneca plc (AZN) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? AstraZeneca plc trades at $167.01 (market cap $253.13B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $60.4. The key difference: AstraZeneca plc pays a 1.92% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | JEPQ | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $61.46 |
52-Week Low | $137.44 | $53.77 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JEPQ trades at $59.59, down 1.52% on the day, with a neutral technical signal overall. The fund provides Nasdaq-100 exposure with a covered-call strategy aimed at generating monthly income, highlighted by recent dividend payments. News coverage focuses on its high distribution yield and role in retirement portfolios, though some articles question its long-term performance versus the underlying index.
The outlook balances high income potential against capped upside in strong bull markets. Key risks include underperformance during tech rallies and dependence on options income. Analyst sentiment is mixed, weighing yield attractiveness against total return trade-offs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
